Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JJ.

Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks.

Investors Business Daily

If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Johnson & Johnson Stock: Here’s the Level to Buy, and It’s a Steal

Johnson & Johnson stock is hitting its lowest level since March. Here's where it's a steal of a deal.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson to stop selling talc-based powder after cancer lawsuits

Lawsuits have claimed product contains asbestos and causes cancer which company denies

Evening Standard

South Africa reports first death causally linked to COVID vaccine

South Africa's health regulator reported on Thursday a causal link between the death of an individual and Johnson Johnson's (JJ) COVID-19 vaccine, the first time such a direct link has been made in the country.

Reuters

Stock Market Rally Breaks Higher; Tesla, Netflix, Snap, United Airlines Key Earnings: Weekly Review

The stock market rally gained steam, breaking above key levels. Tesla soared on earnings, but the Fed and a big week of results loom.

Investors Business Daily

Manchester's first vegan fish and chip shop forced to close

The owner has blamed rising fuel and stock costs, as well as the cost of living crisis in an emotional statement

Manchester Evening News

Read news from The Economist, FT, and more,
with one subscription

Morning Brief: Top Financial Stories Dominating on Tuesday, June 7

Reuters

Benzinga

J&J Serves Notice To Emergent For Terminating COVID-19 Shot Contract As Two Accuse Each Other Of Breach Of Agreement

Johnson & Johnson (NYSE: JNJ) has made another move towards severing its Covid-19 vaccine manufacturing ties with contract manufacturer Emergent Biosolutions, Inc. (NYSE: EBS).

Benzinga

US move affects Africa's vax drive

The US Food and Drug Administration's recent decision to limit the use of the Johnson & Johnson Covid-19 vaccine to adults who cannot or will not get another vaccine will have profound consequences for African countries. The FDA said its move reflected the risk that the vaccine might cause a…

Bangkok Post

Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract

Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines.

Benzinga

Alex Jones promotes false conspiracy that monkeypox outbreak is due to Covid-19 vaccines

The monkeypox outbreak theory is just the latest unproven claim to be promoted by the anti-vaxer

The Independent UK

Alex Jones promotes false conspiracy that monkeypox outbreak is due to Covid-19 vaccines

The monkeypox outbreak theory is just the latest unproven claim to be promoted by the anti-vaxer

The Independent UK

Psychedelics Atai Life Sciences: Optimizing Drug Development By Avoiding Big Pharma's Past Missteps

In the early days of the psychedelics industry, financial reports mean very little. Unless a company wildly misses its operating spending budget and hemorrhages cash by more than expected, the report is basically a synopsis of a given company’s highlights and milestones over the previous quarter.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

A year on, Quad initiative for 1 billion India-made vaccines runs into rough weather

Production of Johnson & Johnson jab at Hyderabad-based firm’s facility stalled over indemnity and safety issues

Investors Business Daily

How Stocks React To News Can Tell More About The Stock Than The News

How a stock reacts to earnings or other news can tell an investor more about the company than the news itself.

Benzinga

FDA Limits Use of Johnson & Johnson's COVID-19 Vaccine to Certain Individuals - All You Should Know

The FDA said it was limiting the use of Johnson & Johnson's (NYSE:

The Independent UK

AP News Digest 4 a.m.

Here are the AP’s latest coverage plans, top stories and promotable content. All times EDT. For up-to-the minute information on AP’s coverage, visit Coverage Plan at https://newsroom.ap.org.

Get all your
news in one place.

100’s of premium titles.
One news app.

Asharq Al-Awsat

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

McClatchy Washington Bureau

FDA limits use of Johnson & Johnson COVID vaccine over blood clot risks, agency says

The use of Johnson and Johnson’s COVID-19 vaccine, also known as Janssen, has been limited to “certain individuals” over rare blood clot risks, the U.S. Food and Drug Administration announced Thursday, May 5.

WEKU

FDA limits Johnson & Johnson's COVID vaccine to some people due to blood clot risk

The chances of dying following after receiving the Janssen vaccine is about 1:2,000,000. But with multiple COVID-19 vaccines available, the FDA is limiting the use of the J&J vaccine.

The Independent UK

FDA restricts J&J's COVID-19 vaccine due to blood clot risk

U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots

Benzinga

Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements

Emergent BioSolutions Inc (NYSE:EBS) reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million. The decrease is primarily due to the company's decision to initiate maintenance and…

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, April 27

Reuters Kellogg Sues British Government Over New Sugar Rules

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.